Home » Newsletters » BioWorld Science

BioWorld Science

April 14, 2014

View Archived Issues

Phase II of RUTI vaccine to prevent active tuberculosis

New clinical data on alirocumab for hypercholesterolemia presented

RG-7287 inhibits tumor growth in xenograft models

Selvita's novel dual Mnk1/2 inhibitors show potential in preclinical models of cancer

Adocia reports results from phase IIa study of ultra-fast-acting BioChaperone lispro

Preliminary data reported for clinical study of UX-003 in mucopolysaccharidosis type VII

Antibody-drug conjugate collaboration between PolyTherics and MacroGenics extended

Chemilia discloses new tubulin polymerization inhibitors for cancer

Abbott completes enrollment in three further trials of Absorb

New Notch signaling inhibitors designed by Bristol-Myers Squibb

Sofosbuvir/GS-5816 gives SVR12 rates > 90% across all HCV genotypes

Pfizer discloses novel Abeta production inhibitors

GlaxoSmithKline presents promising preclinical data for GSK-2878175

Vivolux present agents for solid tumor treatment

Novel tankyrase inhibitors disclosed by Cellzome

Impax resubmits NDA for IPX-066

PCI Biotech announces completion of first dose cohort in phase I/II cholangiocarcinoma trial

German scientists disclose new MetAP 2 inhibitors

Lytix Biopharma forms Pharmasum Therapeutics to focus on dementia

Study will evaluate TSO in pediatric patients with autism spectrum disorder

Improved detection of localized prostate cancer with technetium Tc 99m trofolastat

Protocol for phase IIb study of metadoxine extended release sent to FDA

CHART-1 trial of C-Cure authorized to begin in Ireland

Cytos immunomodulator fails to achieve primary endpoint in phase IIb asthma study

Merrion to initiate pivotal phase III study of oral zoledronic acid in breast cancer

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...